UNSPSC 51334308: Chlorprothixene citrate

This classification denotes an antipsychotic agent C18H18ClNS.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 814JN9G41D, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (3z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), but more generally known as chlorprothixene citrate, which bears US NIH Compound Identifier 24892862. Most nations, for tariff and trade purposes, schedule chlorprothixene citrate under HS 29349910 and SITC 51579.

As of Q4 2014, CHLORPROTHIXENE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51334308 Chlorprothixene citrate is a Commodity code representing a specific antipsychotic pharmaceutical product. However, the recent state and local contract opportunities tagged under this code show no solicitations for chlorprothixene citrate itself. Instead, the opportunities document purchases of naloxone, safe drug deactivation systems, and broad generic pharmaceutical and over-the-counter product agreements—none of which are chlorprothixene citrate. The code appears to reflect a data-tagging mismatch rather than active procurement demand for this specific drug in the state and local market.

The three recent opportunities show activity across health and human services agencies: Seminole County, Florida (county-level health procurement), the Texas Health and Human Services Commission (state-level), and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative vehicle). The geographic spread includes Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (a historical date inconsistent with the posting date). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities rather than procure a specific drug. The Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. Given the disconnect between the code and the actual commodities in recent opportunities, this code does not reflect meaningful current procurement demand in state and local markets.